Molecular and traditional chemotherapy: A united front against prostate cancer

作者：Singh P; Yam M; Russell P J; Khatri A^*

来源：Cancer Letters, 2010, 293(1): 1-14.

DOI：10.1016/j.canlet.2009.11.019

• Chemotherapy
• Docetaxel
• Molecular chemotherapy
• Purine nucleoside phosphorylase
• Gene directed pro-drug enzyme therapy
• Conditionally replicating adenovirus

Castrate resistant prostate cancer (CRPC) is essentially incurable. Recently though, chemotherapy demonstrated a survival benefit (similar to 2 months) in the treatment of CRPC. While this was a landmark finding, suboptimal efficacy and systemic toxicities at the therapeutic doses warranted further development. Smart combination therapies, acting through multiple mechanisms to target the heterogeneous cell populations of PC and with potential for reduction in individual dosing, need to be developed. In that, targeted molecular chemotherapy has generated significant interest with the potential for localized treatment to generate systemic efficacy. This can be further enhanced through the use of oncolytic conditionally replicative adenoviruses (CRAds) to deliver molecular chemotherapy. The prospects of chemotherapy and molecular-chemotherapy as single and as components of combination therapies are discussed.

• 出版日期2010-7-1